Navigation Links
Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
Date:12/18/2013

SEATTLE, Dec. 18, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that CTI has received the remaining $5 million from Hercules Technology Growth Capital, Inc. (NYSE: HTGC) available under the existing loan agreement that was established in March 2013.  Further information with respect to this loan with Hercules will be available in a Current Report on Form 8-K that will be filed by CTI with the Securities and Exchange Commission. 

About Cell Therapeutics, Inc.

Cell Therapeutics (NASDAQ and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

About Hercules Technology Growth Capital, Inc.

Hercules Technology Growth Capital, Inc., (NYSE: HTGC) is the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets, including technology, biotechnology, life science and energy and renewables technology industries, at all stages of development. Since inception (December 2003), Hercules has committed more than $3.9 billion to over 250 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. For more information please visit www.htgc.com, or call 650-289-3060.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.  Such statements are subject to a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities.  Such statements include, but are not limited to, statements regarding CTI's expectations with respect to the development of CTI.  Risks that contribute to the uncertain nature of the forward-looking statements include, among others, risks associated with the biopharmaceutical industry in general and with CTI and its product and product candidate portfolio in particular including, among others, risks associated with the following: that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials, that CTI cannot predict or guarantee the outcome of preclinical and clinical studies, that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities, that CTI may experience delays in the commencement of preclinical and clinical studies, risks related to the costs of developing pacritinib and CTI's other product candidates, and other risks, including, without limitation, competitive factors, technological developments, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI may not achieve previously announced goals and objectives as or when projected, that CTI's average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K.  Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

Contacts:
Monique Greer
+1 206-272-4343
mgreer@ctiseattle.com

Ed Bell
+1 206-282-7100
ebell@ctiseattle.com

In Europe:

CTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706
lvilla@cti-lifesciences.com
CTI_EUInvestors@CTI-Lifesciences.com

 


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Announces Executive Transitions
2. Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
3. Relmada Therapeutics Inc. Appoints Douglas J. Beck As Chief Financial Officer
4. Echo Therapeutics Announces Strategic Partnership with Medical Technologies Innovation Asia (MTIA)
5. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
6. United Therapeutics Receives Subpoena From Office of Inspector General
7. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
8. Boston Therapeutics, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
9. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
10. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
11. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 Fenita ... Who as a Pinnacle Lifetime Professional in the ... Account Manager at Turing Pharmaceuticals, AG. Her skills ... and relationship building.                ... than 25 years of experience as a highly ...
(Date:8/2/2017)... , Aug. 2, 2017  Life Flight Network and PeaceHealth ... agreement improves patient care and operational efficiency for patients at ... , Cottage Grove , and ... transportation. PeaceHealth and Life Flight Network work collaboratively to move ... transport, or when a time sensitive emergency exists. ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
Breaking Medicine Technology:
(Date:8/23/2017)... ... August 23, 2017 , ... CEFEX, the Centre ... to the standards representing best practices in the retirement plan industry. The independent ... and helps to verify that NFP’s retirement division focuses on putting clients’ interests ...
(Date:8/23/2017)... Mesa, Arizona (PRWEB) , ... August 23, 2017 ... ... is in the top 20% of hospitals nationally that earned the designation of ... annual list. An overall rating of high performing indicates a hospital was significantly better ...
(Date:8/23/2017)... ... August 23, 2017 , ... TSC ... Awards® - for Risk Management Solution Innovations and Security Solution for Government Innovations. ... released in 2017 and its DHS SAFETY Act-designated enterprise security assessment approach. , ...
(Date:8/22/2017)... ... August 22, 2017 , ... The ... health is as simple as eating healthy foods. But this well-known piece of ... making insulin, or breaking apart carbohydrates—depends not only on properties of the food ...
(Date:8/22/2017)... ... ... Nurses at Apple Rehab Watch Hill , a nursing and rehabilitation ... in Closed Pulse Irrigation™ (CPI) for wound care. This qualifies Apple ... Medicare and Medicaid Services, to have a CPI machine that will provide better quality ...
Breaking Medicine News(10 mins):